Childhood acute lymphoblastic leukemia (ALL), one of the first malignant diseases for which
large-scale therapeutic trials were conducted, has served as a paradigm for cancer research …

The therapy of acute lymphoblastic leukemia (ALL) in the adolescent and young adult
patient presents several challenges. Clinicians who care for these patients need to be …

Trial ALL-BFM 90 was designed to improve outcome in patients with childhood acute
lymphoblastic leukemia (ALL) by using a reduced treatment regimen. Patients were stratified …

Four thousand, four hundred and forty eligible children of up to 18 years of age were treated
in four consecutive trials between 1981 and 1995 with the treatment protocols of the Berlin …

Background Children with Philadelphia chromosome–positive acute lymphoblastic leukemia
(Ph-positive ALL) have a poor prognosis, and there is no consensus on the optimal …

Abstract The Dana-Farber Cancer Institute (DFCI) Childhood ALL Consortium Protocol 95-
01 was designed to minimize therapy-related morbidity for children with newly diagnosed …

PURPOSE To describe the incidence of acute neurotoxicity (NT) in children with lower risk B-
precursor acute lymphoid leukemia (ALL) treated with intermediate-dose methotrexate …

We analyzed the long-term outcome of 4865 patients treated in Studies 82, 87, 88, 91 and
95 for childhood acute lymphoblastic leukemia (ALL) of the Italian Association of Pediatric …

Purpose Between September 1991 and May 1997, within the International Berlin-Frankfurt-
Muenster Study Group (I-BFM-SG), a randomized study was performed aimed at assessing …

Context Pediatric acute lymphoblastic leukemia (ALL) is the prototype for a drug-responsive
malignancy. Although cure rates exceed 80%, considerable unexplained interindividual …